Our pipeline & IP

EpiAxis is developing a series of products targeting LSD1, PKC theta and PD1/PDL1.  Please contact j.chrisp@epiaxistherapeutics.com to discuss partnering/licensing. 

Our intellectual property 

Our wholly owned IP is broad and includes strong coverage for our therapeutic portfolio and includes a dominating position for LSD1 inhibitors used in combination with surgery, radiotherapy or chemotherapy or immunotherapy.